Comparative Pharmacology
Head-to-head clinical analysis: BICNU versus CARMUSTINE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: BICNU versus CARMUSTINE.
BICNU vs CARMUSTINE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Carmustine (BCNU) is a nitrosourea alkylating agent that crosslinks DNA and RNA, inhibits DNA synthesis, and carbamoylates proteins.
Carmustine is a nitrosourea alkylating agent that forms interstrand crosslinks in DNA, thereby inhibiting DNA replication and transcription. It is cell cycle phase-nonspecific and also has some alkylating activity against RNA and proteins.
150-200 mg/m2 IV every 6 weeks, administered as a single dose or divided into 2 doses on consecutive days.
150-200 mg/m2 intravenously every 6 weeks as a single dose or divided into daily doses of 75-100 mg/m2 on 2 consecutive days every 6 weeks.
None Documented
None Documented
The terminal elimination half-life of BCNU is 15-30 minutes for the parent drug, but active metabolites persist with a half-life of 5-6 hours. Due to rapid degradation, the overall cytotoxic effect is prolonged.
Clinical Note
moderateCarmustine + Digoxin
"Carmustine may decrease the cardiotoxic activities of Digoxin."
Clinical Note
moderateCarmustine + Digitoxin
"Carmustine may decrease the cardiotoxic activities of Digitoxin."
Clinical Note
moderateCarmustine + Deslanoside
"Carmustine may decrease the cardiotoxic activities of Deslanoside."
Clinical Note
moderateCarmustine + Acetyldigitoxin
"Carmustine may decrease the cardiotoxic activities of Acetyldigitoxin."
Terminal half-life 15-30 minutes (biphasic: initial 1-4 min, terminal due to slow release from tissues); prolonged with hepatic impairment
Renal excretion accounts for approximately 60-70% of the administered dose, with about 10% excreted unchanged. Biliary/fecal excretion accounts for less than 10%.
Renal (60-70% as metabolites); <1% unchanged; biliary/fecal minimal (~6%)
Category C
Category C
Alkylating Agent Antineoplastic
Alkylating Agent Antineoplastic